BELGRADE, MT, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the second quarter ended June 30, 2018. Summary of Second Quarter 2018 Financial Highlights and Recent Announcements: Revenue for the second quarter of 2018 was $18.7 million, down from $21.4 million for the second quarter of 2017 Gross Margin for the second qua…

BELGRADE, MT, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announces that it will release its financial results for the quarter ended June 30, 2018, after the close of the financial markets on Tuesday, August 7, 2018. An accompanying conference call will be conducted by Carl O'Connell, chief executive officer, and Laura Kendall, interim chief financial officer, to …

BELGRADE, MT, July 10, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Kevin Brandt to the new executive position of Chief Commercial Officer effective July 9, 2018. “We are excited to have such a talented and experienced executive officer join our team,” said Carl O’Connell, chief executive officer of Xtant. “Kevin’s past accomplishments …

BELGRADE, MT, June 19, 2018 (GLOBE NEWSWIRE) -- XtantTM Medical Holdings, Inc. (NYSE American: XTNT) announces that the subscription period for its previously announced rights offering (the “Offering”) of shares of the Company’s common stock at a subscription price of $7.20 per share expired on June 18, 2018, and these rights are no longer exercisable. Based on the review of preliminary results provided by the Company’s subscription agent, Corporate Stock Transfer, Inc., Xtant Medical…

BELGRADE, MT / ACCESSWIRE / May 21, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for InTice™-C Porous Titanium Cervical Interbody System.InTice-C is designed using OsteoSync Ti, a best-in-class, cost-effective, highly porous titanium scaffold material for improved implant fixation. The material more closely resembles the bioscaff…

BELGRADE, MT / ACCESSWIRE / May 8, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the first quarter of 2018.First Quarter 2018 Financial Highlights and Recent Accomplishments: Revenue for the first quarter 2018 was $17.9 million, down from $22.1 million for the first quarter of 2017 Gross Margin for the first quarter 2018 was 68.2%, compared to 67.5…

BELGRADE, MT / ACCESSWIRE / May 2, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the quarter ended March 31, 2018, after the close of the financial markets on Tuesday, May 8, 2018.An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and Laura Kendall, Interim Chief Financial Officer…

BELGRADE, MT / ACCESSWIRE / April 18, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has entered into an agreement with Healthcare International Partners (HIP), in Miramar, Florida for expanding distribution in Latin American markets. The three-year agreement with HIP will focus on executing Xtant Medical's global strategy, supporting current distribution partners, recruiting partn…

BELGRADE, MT / ACCESSWIRE / April 17, 2018 / Xtant™ Medical Holdings, Inc. (NYSE American: XTNT) announced today that it has set April 27, 2018 as the record date for a proposed rights offering of its shares of common stock.At the commencement of the rights offering, each holder of common stock will receive 0.0869816 non-transferable subscription rights for each share of common stock held on the record date. Each whole subscription right will entitle the holder to purchase one share of the …

BELGRADE, MT / ACCESSWIRE / April 2, 2018 / Xtant™ Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported its financial results for the period ended December 31st, 2017.''2017 represented a significant year for the Company as we completed transformational restructuring activities that were necessary for the future growth of Xtant Medical,'' said Carl O'Connell, Chief Executive Officer, ''Our team has wo…

BELGRADE, MT / ACCESSWIRE / March 27, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2017, after the close of the financial markets on Monday, April 2, 2018.An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and Laura Kendall, Int…

Reports Pro Forma Stockholders’ Equity of approximately $47.4M as of 2/15/18 Xtant has regained compliance with the NYSE American listing standards BELGRADE, Mont., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today reported a positive stockholders’ equity of approximately $47.4M as of February 15, 2018, on an unaudited, pro forma basis, which reflects Xtant’s: (…